Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 NVE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1424202 (State or ot ...

NVE Corp (NASDAQ:NVEC) Q4 2021 Earnings Conference Call May 5, 2021 5:00 PM ET Company Participants Daniel Baker - CEO, President & Director Curt Reynders - CFO, Treasurer & Secretary Conference Call Participants Jeffrey Bernstein - Cowen Daniel Baker Good afternoon and welcome to our conference call for the quarter and fiscal year ended March 31, 2021. This is Dan Baker, President and CEO of NVE Corporation. As always, I'm joined by Curt Reynders, our Chief Financial Officer. This call is being webcast liv ...

Financial Performance - Total revenue for fiscal 2021 decreased by 16% compared to fiscal 2020, primarily due to a 16% decrease in product sales and an 18% decrease in contract research and development revenue [99]. - Net income for fiscal 2021 was 54.7% of total revenue, down from 57.2% in fiscal 2020, reflecting a 19.5% decrease year-over-year [101]. - The impact of the COVID-19 pandemic significantly affected total revenue and net income for fiscal 2021, particularly in the medical devices sector [102]. Cash Flow and Liquidity - Cash and cash equivalents increased to $10,427,340 as of March 31, 2021, up from $8,065,594 as of March 31, 2020, driven by $13,364,832 in net cash provided by operating activities [103]. - Net cash provided by operating activities was $13,364,832 for fiscal 2021, compared to $15,895,773 for fiscal 2020, indicating a decrease in cash flow from operations [104]. - The company plans to pay a cash dividend of $1.00 per share, totaling $4,833,232, to be paid on May 31, 2021, subject to Board approval [109]. Expenses and Taxation - Research and development expenses decreased by 14% in fiscal 2021, attributed to the completion of certain new-product development projects [100]. - The effective tax rate for fiscal 2021 was 18% of income before taxes, compared to 16% for fiscal 2020, reflecting changes in tax benefits [101]. Accounts Receivable and Deferred Tax Assets - Accounts receivable decreased by $729,737, primarily due to the timing of sales to and payments from customers [105]. - The company had $73,538 in net deferred tax assets as of March 31, 2021, down from $108,119 as of March 31, 2020 [97].

NVE Corporation (NASDAQ:NVEC) Q3 2021 Earnings Conference Call January 20, 2021 5:00 PM ET Company Participants Daniel Baker - President and Chief Executive Officer Curt Reynders - Chief Financial Officer Conference Call Participants Jeff Bernstein - Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the NVE Conference Call on Third Quarter Results. At this time, all participants are in a listen-only mode. After the speakers??? presentation, there will be a question-and-answer se ...

FORM 10-Q 10-Q 1 NVE_Q3_FY2021_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED DEC. 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11409 Valley View Road, Eden Prairie, Minnesota 55344 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 (Address of principal executive offices) (Z ...

NVE Corporation (NASDAQ:NVEC) Q2 2021 Earnings Conference Call October 21, 2020 5:00 PM ET Company Participants Daniel Baker ??? President and Chief Executive Officer Curt Reynders ??? Chief Financial Officer Conference Call Participants Jeff Bernstein ??? Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the NVE Conference Call on Second Quarter Results. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer ...

10-Q 1 NVE_Q2_FY2021_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED SEPT. 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 NVE CORPORATION (Exact name of ...

Financial Data and Key Metrics Changes - Revenue for the quarter ended June 30, 2020, decreased by 27% compared to the prior year, primarily due to a 28% decrease in product sales, partially offset by a 10% increase in contract R&D revenue [4][6] - Net income for the quarter was $2.41 million or $0.50 per diluted share, down from $3.61 million or $0.74 last year, with comprehensive income decreasing only 13% to $3.65 million [9][10] - Cash flow from operations was $3.17 million, compared to $4.54 million in the same quarter last year [10] - The balance sheet remains strong, with cash plus marketable securities decreasing slightly to $70.6 million as of June 30, compared to $70.8 million as of March 31 [11] Business Line Data and Key Metrics Changes - Product sales decreased by 28%, while contract R&D revenue increased by 10% due to the timing of contract completion [6] - R&D expenses decreased by 9%, while SG&A expenses increased by 8% due to staffing changes for more sales activities [7][8] Market Data and Key Metrics Changes - The company expects two more quarters with significant revenue decreases due to delayed orders from important customers, especially in the medical device sector [7] - The pandemic has significantly impacted medical device markets, as many elective procedures were postponed [6] Company Strategy and Development Direction - The company is focused on preserving its workforce, continuing to invest in new product development, and maintaining generous dividends despite the pandemic [5] - New product launches included a high-field TMR magnetic sensor and new power conversion products, indicating ongoing innovation [12][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the significant impact of the COVID-19 pandemic but expressed optimism about the long-term future, particularly in critical sectors like medical devices and automation [4][5] - The company is positioned to recover some lost business once the pandemic subsides, with hopes for recovery in early 2021 [7] Other Important Information - The company launched four new products during the quarter, demonstrating a commitment to innovation despite challenges [12] - The annual shareholders meeting will be held via webcast on August 6, 2020 [19] Q&A Session Summary Question: Update on automotive developments and bacteria sensors - Management is working on automotive projects, specifically a current sensor for hybrid electric vehicles, which has a lengthy approval process [28] - Challenges remain with the optimal biochemistry for bacteria sensors, but the technology has potential applications in food safety and medical diagnostics [30][32] Question: Hearing aid market updates - No new wins reported, but the company continues to invest in technology for the hearing aid market, which is expected to grow post-pandemic [44][45] Question: Visibility on PUF orders from military - Interest in Physical Unclonable Functions (PUFs) remains, with ongoing investment in anti-tamper systems for military applications [62] Question: Tax rate expectations - The expected tax rate for the rest of the fiscal year is in the 17% to 18% range [63]

10-Q 1 NVE_Q1_FY2021_10Q.htm QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-12196 NVE CORPORATION (Exact name of regist ...

NVE Corporation (NASDAQ:NVEC) Q4 2020 Earnings Conference Call May 6, 2020 5:00 PM ET Company Participants Daniel Baker ??? President and Chief Executive Officer Curt Reynders ??? Chief Financial Officer Conference Call Participants Jeff Bernstein ??? Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the NVE Conference Call on Fourth Quarter and Fiscal Year Results. At this time, all participant lines are in a listen-only mode. After the speakers??? presentation, there will be q ...